Transient reduction in coronary perfusion pressure in the isolated mouse heart increases microvascular resistance (paradoxical vasoconstriction) by an endotheliummediated mechanism. To assess the presence and extent of paradoxical vasoconstriction in hearts from normal and diabetic rats and to determine whether increased heme oxygenase (HO)-1 expression and HO activity, using cobalt protoporphyrin (CoPP), attenuates coronary microvascular response. Male Wistar rats were rendered diabetic with nicotinamide/streptozotocin (NA/STZ) for 2 weeks and either CoPP or vehicle was administered, by intraperitoneal injection, daily for 3 weeks (0.5 mg/100 gm body wt). The isolated beating non-working heart was submitted to transient low perfusion pressure (20 mm Hg) and coronary resistance (CR) was measured. During low perfusion pressure, CR increased and was associated with increased lactate release. In diabetic rats, CR was higher, HO-1 expression and endothelial nitric oxide synthase (eNOS) were downregulated, and inducible nitric oxide synthase (iNOS) and superoxide anion (O 2 -) were upregulated. After 3 weeks of CoPP treatment, HO activity was significantly increased in the heart. Upregulation of HO-1 expression and HO activity by CoPP resulted in the abolition of paradoxical vasoconstriction and a reduction in oxidative ischemic damage. In addition, there was a marked increase in serum adiponectin. Elevated HO-1 expression was associated with increased expression of cardiac eNOS, B-cell leukemia/lymphoma extra long (Bcl-xL) and phospho activator protein kinase (pAKT) levels, and decreased levels of iNOS and malondialdehyde (MDA). These results suggest a critical role for HO-1 in microvascular tone control and myocardial protection during ischemia in both normal and mildly
INTRODUCTION
According to classical concepts of autoregulation, coronary microvessels dilate in response to a reduction in perfusion pressure so as to preserve flow. Beneath a certain pressure level, the exhaustion of this mechanism causes flow to decline and myocardial ischemia to ensue. Recently, both clinical and experimental studies (26; 48) have demonstrated a "paradoxical" coronary microvascular constriction during severe reduction in perfusion pressure and myocardial ischemia. It is not known whether this may be a naturally occurring response to severe hypotension and ischemia, possibly intended to preserve capillary pressure, or whether it may be caused or enhanced by the presence of endothelial dysfunction, hence, aggravating myocardial ischemia.
In the isolated mouse model, "paradoxical coronary vasoconstriction" has been reproduced by perfusion at low pressure and the endothelium appears to play a pivotal role in this vascular response, which involves the cooperative vasoconstrictive actions of the nitric oxide (NO) and endothelin systems (26). In particular, nitric oxygen synthase (NOS) inhibition or the administration of reactive oxygen species (ROS) scavengers has been able to antagonize the paradoxical vasoconstrictive response to low pressure. This observation led to the hypothesis that, during ischemia, NO released in the vascular wall and possibly in the myocardium can be converted by ROS to a reactive species with constrictive properties, such as peroxynitrite, with a simultaneous reduction of NO availability and activation of the vasoconstrictive pathway of the endothelin.
Type 2 diabetes is a clinical condition, the prevalence of which is rapidly growing in Western countries. It has been estimated that, by the year 2030, there will be almost The recognition that heme oxygenase (HO)-1 is present in the heart and induced by various oxidants, including metals, signifies the importance of this enzyme in cradioprotection (37;3). Cardioselective overexpression of HO-1 exerts a cardioprotective effect after myocardial ischemia-reperfusion in mice (55). The robust ability of HO-1 to protect against oxidative insult in cardiovascular diseases, including diabetes, suggests that HO-1 may be a target for pharmacological intervention in the alleviation of vascular diseases (1). The protective effects of HO-1 arise from its capacity to increase degradation of the heme moiety from destabilized heme proteins (36) and to generate biliverdin and bilirubin, which possess potent antioxidant properties (51) and display cytoprotective properties in the cardiovascular system (10; 18). Carbon monoxide (CO) is not an antioxidant (59) but has a beneficial effect on vascular relaxation and causes the induction of antioxidant genes, including superoxide dismutase and glutathione levels (1; 13; 46; 53).
HO-1 and coronary microcirculation 8 Isolated heart preparation. Rats were anaesthetized with a mixture of ether and air and heparinized via the left femoral vein (250 units/kg) 72 hours after the last CoPP or vehicle injection. The heart was rapidly excised and placed in perfusion medium.
Within 30 sec, the aorta was attached to a stainless steel cannula, the pulmonary artery was incised to permit adequate drainage, and the heart was perfused normothermically (37ºC) by the method of Langendorff at a perfusion pressure equivalent to 80 mm Hg.
The perfusion medium was Krebs-Henseleit buffer (KHB) having the following composition in mM: NaCl 120.0, NaHCO Homogenates were centrifuged at 13,000 x g for 15 min at 4ºC, supernatant was isolated, and protein levels were assayed by the Bradford method. One volume of supernatant was mixed with 1 volume of 0.66% (w/v) thiobarbituric acid (TBA), and the mixture was boiled for 15 min. After cooling in tap water, the mixture was read at 535 nm, and the TBA-MDA adduct was calculated by using a molar absorption coefficient of Determination of HO, eNOS, iNOS, pAKT and serum adiponectin. Frozen hearts were pulverized under liquid nitrogen and placed in a homogenization buffer (10 mM phosphate buffer, 250 mM sucrose, 1 mM EDTA, 0.1 mM PMSF and 0.1% tergitol, pH 7.5). Homogenates were centrifuged at 27,000 x g for 10 min at 4ºC, supernatant was isolated, and protein levels for HO-1/HO-2, eNOS, iNOS and pAkt, as well as O 2 -levels and HO activity, were measured as previously described (5; 24). Adiponectin assayed in serum obtained from venous blood samples obtained immediately before heart excision was determined using ELISA assay (Pierce Biotechnology, Inc, Woburn, MA). HO-1 and coronary microcirculation 10 groups and between different study conditions was determined by using a two-way ANOVA followed by the Fisher's exact test; p<0.05 was considered significant. Adiponectin levels were lower in diabetic (3.88±1.04 µg/ml) compared to 7.1±0.76 µg/ml in control rats (p<0.05). CoPP administration significantly increased serum adiponectin (to 12.7±2.56 µg/ml) in diabetic rats compared to untreated diabetic rats (p<0.01). To ascertain whether the CoPP-mediated increase in adiponectin levels was related to increased HO activity, we co-administered SnMP (tin mesoporphyrin), an inhibitor of HO activity, to D-CoPP rats, which resulted in inhibition of HO activity and serum adiponectin release (data not shown). In the present study, paradoxical vasoconstriction was also observed, for the first time, in hearts isolated from mildly diabetic rats, which showed higher coronary resistance values compared to controls under all conditions studied and when considering absolute values (Table 1) . The changes decrease when considered as a percentage; however, this comparison also shows higher coronary resistance values in diabetic animals compared to controls. As judged by lactate release, no striking
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Copyright Information HO-1 and coronary microcirculation 16 differences were apparent between control and diabetic animals in the severity of ischemia induced by perfusion at low pressure.
A major finding of the study is that pharmacological induction of HO-1 expression and increased HO activity, by CoPP, completely prevented paradoxical vasoconstriction in both control and diabetic rats and decreased lactate release, an effect that was particularly evident in the diabetic group. After CoPP administration, there is a clear reduction in both MDA and superoxide in diabetic hearts; conversely, MDA is reduced but superoxide is not reduced in the normal hearts. This may be due to several factors.
For example, NADPH oxidase, which is a critical source of superoxide, may be present at low levels in the normal heart and CoPP may not further decrease superoxide production in control animals, as it is already very low. In diabetes, in contrast to normal groups, there is activation of NADPH oxidase and mitochondrial production of ROS, In the present study, CoPP administration to diabetic rats resulted in a significant increase in serum adiponectin levels, which was blocked by the administration of the HO inhibitor SnMP. This increase in adiponectin may precondition the heart to be more Thus, the effect of CoPP treatment increasing adiponectin levels in diabetic animals, which we report here, suggests the possible beneficial role of adiponectin in diabetes. This conclusion stems from the fact that the HO-1-mediated increase in adiponectin provides the heart with a tolerance to oxidants thus enabling the isolated heart to be resistant to stress situations. It is therefore possible that, in addition to increased levels of bilirubin (anti-oxidant) and CO (anti-apoptotic), compounds regarded as cytoprotective, observed after HO-1 induction, increased levels of adiponectin also function to protect the cell against toxic insults. This is the first report to demonstrate that increased levels of adiponectin are associated with the induction of HO-1 and, as such, offer a new therapeutic approach to the treatment of diabetes.
The present study establishes the direct action of HO-1 in enhancing eNOS while downregulating iNOS cardiac protein levels in this model of low-pressure ischemia. 
